sur Mainz BioMed N.V.
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data at ASCO 2024
Mainz Biomed N.V. will present new pooled colorectal cancer screening data at the ASCO 2024 Annual Meeting. This presentation will showcase findings from 690 subjects, making it the largest study to date for the company. The data, derived from the ColoFuture and eAArly DETECT studies, demonstrate a 92.3% sensitivity for detecting colorectal cancer and 82.3% for advanced precancerous lesions.
These studies utilized a novel combination of mRNA biomarkers, the Fecal Immunochemical Test (FIT), and a proprietary AI algorithm. This innovative approach aims to enhance diagnostic accuracy for colorectal cancer and advanced precancerous lesions. The poster presentation, led by Dr. D. Kim Turgeon, will take place on June 1, 2024.
Mainz Biomed's goal is to revolutionize colorectal cancer screening, potentially reducing cancer mortality rates globally. Additional details and updates can be found on the company's official website.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.